Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 6, 2008, Pages 1087-1093

  Falorio, Simona ^a   Angrilli, Francesco ^a   Fioritoni, Giuseppe ^a  

^a Ospedale Civile di Pescara   (Italy)

Author keywords

Amenorrhea; Gonadotropin releasing hormone analog; Hodgkin lymphoma; Pregnancy

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; ETOPOSIDE; FOLLITROPIN; GEMCITABINE; GONADORELIN DERIVATIVE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; NAVELBINE; PREDNISONE; PROCARBAZINE; TRIPTORELIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CONCEPTION; DRUG DOSE ESCALATION; FEMALE; FEMALE INFERTILITY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MANTLE FIELD RADIOTHERAPY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; INFERTILITY, FEMALE; LUTEOLYTIC AGENTS; NEOPLASM RECURRENCE, LOCAL; OVARIAN FAILURE, PREMATURE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REPRODUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRIPTORELIN;

EID: 46749136110     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802035982     Document Type: Article

References (40)

1. Sklar, C. (2005) Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr, 34, pp. 25-27.
2. Byrne, J. (1999) Infertility and premature menopause in childhood cancer survivors. Med Pediatr Oncol, 33, pp. 24-28.
3. Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L. Klimm, B. et al. (2005) Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 23, pp. 7555-7564.
4. De Bruin, M. L., Huisbrink, J., Hauptmann, M., Kuenen, M. A., Quvens, G. M. van't Veer, M B et al. (2008) Treatment-related risk factors for premature menopause following Hodgkin's lymphoma. Blood, 111, pp. 101-108.
5. Haukvik, U. K., Dieset, I., Bjoro, T., Holte, H. and Fosså, S. D. (2006) Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol, 17, pp. 1428-1433.
6. Wallace, W. H., Anderson, R. A. and Irvine, D. S. (2005) Fertility preservation for young patients with cancer: Who is at risk and what can be offered. Lancet Oncol, 6, pp. 209-218.
7. Gougeon, A. (1986) Dinamics of follicular growth in the human: A model from preliminary results. Hum Reprod, 1, pp. 81-87.
8. Lee, S. J., Schover, L. R., Partridge, A. H., Patrizio, P., Wallace, W. H. Hagerty, K. et al. (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol, 24, pp. 2917-2931.
9. Warne, G. L., Fairley, K. F., Hobbs, J. B. and Martin, F. I. (1973) Cyclophosphamide-induced ovarian failure. N Engl J Med, 289, pp. 1159-1162.
10. Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T. and Aoky, Y. (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer, 39, pp. 1403-1409.
11. Kreuser, E. D., Felsenberg, D., Behles, C., Seibt-Jung, H., Mielcarek, K. Diehl, V. et al. (1992) Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol, 3, pp. 105-110.
12. Fosså, S. D. and Magelssen, H. (2004) Fertility and reproduction after chemotherapy of adult cancer patients: Malignant lymphoma and testicular cancer. Ann Oncol, pp. 259-265.
13. Oktem, O. and Oktay, K. (2007) Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer, 110, pp. 2222-2229.
14. Wallace, W. H., Thomson, A. B., Saran, F. and Kelsey, T. W. (2005) Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys, 62, pp. 738-744.
15. Horning, S. J., Hoppe, R. T., Kaplan, H. S. and Rosenberg, S. A. (1981) Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med, 304, pp. 1377-1382.
16. Aisner, J., Wiernik, P. H. and Pearl, P. (1993) Pregnancy outcome in patients treated for Hodgkin's disease. J Clin Oncol, 11, pp. 507-512.
17. Hodgson, D. C., Pintilie, M., Gitterman, L., Dewitt, B., Buckley, C. A. Ahmed, S. et al. (2007) Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol, 25, pp. 11-15.
18. Damewood, M. D., Hesla, H. S., Lowen, M. and Schultz, M. J. (1990) Induction of ovulation and pregnancy following lateral oophoropexy for Hodgkin's disease. Int J Gynaecol Obstet, 33, pp. 369-371.
19. Pereyra, P. B., Mendez, R JM, Milone, G., Fernandez, I., Kvicala, R. Mila, T. et al. (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol, 81, pp. 391-397.
20. Blumenfeld, Z. (2007) How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist, 12, pp. 1044-1054.
21. Ataya, K., Rao, L. V., Lawrence, E. and Kimmel, R. (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod, 52, pp. 365-372.
22. Sklar, C. A., Mertens, A. C., Mitby, P., Whitton, J., Stovall, M. Kasper, C. et al. (2006) Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study. J Natl Cancer Inst, 98, pp. 890-896.
23. Castelo-Branco, C., Nomdedeu, B., Camus, A., Mercadal, S., Martinez de Osaba, M J and Balasch, J. (2007) Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril, 87, pp. 702-705.
24. Recchia, F., Sica, G., De Filippis, S., Saggio, G., Rosselli, M. and Rea, S. (2002) Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: A phase II pilot study. Anticancer Drugs, 13, pp. 417-424.
25. Franchi-Rezgui, P., Rousselot, P., Espie, M., Briere, J., Pierre Marolleau, J Gisselbrecht, C. et al. (2003) Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J, 4, pp. 116-120.
26. Blumenfeld, Z., Avivi, I., Eckman, A., Epelbaum, R., Rowe, J. M. and Dann, E. J. (2008) Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin's lymphoma. Fertil Steril, 89, pp. 166-173.
27. Blumenfeld, Z., Avivi, I., Linn, S., Epelbaum, R., Ben-Shahar, M. and Haim, N. (1996) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod, 11, pp. 1620-1626.
28. Chapman, R. M., Sutcliffe, S. B. and Malpas, J. S. (1979) Cytotoxic-induced ovarian failure in women with Hodgkin's disease I. Hormone function. JAMA, 242, pp. 1877-1881.
29. Oktay, K., Sonmezer, M., Oktem, O., Fox, K., Emons, G. and Bang, H. (2007) Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing ormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist, 12, pp. 1055-1066.
30. Kitajima, Y., Endo, T., Nagasawa, K., Manase, K., Honnma, H. Baba, T. et al. (2006) Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology, 147, pp. 694-699.
31. Imai, A., Sugiyama, M., Furui, T., Tamaya, T. and Ohno, T. (2007) Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest, 63, pp. 102-106.
32. Morita, Y., Perez, G. I., Paris, F., Miranda, S. R., Ehleiter, D. Haimovitz-Friedman, A. et al. (2000) Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med, 6, pp. 1109-1114.
33. Behringer, K., Wildt, L., Haverkamp, H., Diehl, V., Pfistner, B. Engert, A. et al. (2007) Results of the randomized phase II trial for the reduction of ovarian failure with the use of GnRH-analogues and oral contraceptives in young women (18-40 years) treated with intensive chemotherapy for advanced-stage Hodgkin lymphoma. Haematologica, 92, pp. 63-64.
34. Demeestere, I., Simon, P., Emiliani, S., Delbaere, A. and Englert, Y. (2007) Fertility preservation: Successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist, 12, pp. 1437-1442.
35. Oktay, K., Cil, A. P. and Bang, H. (2006) Efficiency of oocyte cryopreservation: A meta-analysis. Fertil Steril, 86, pp. 70-80.
36. Donnez, J., Dolmans, M. M., Demylle, D., Jadoul, P., Pirard, C. Squifflet, J. et al. (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet, 364, pp. 1405-1410.
37. Meirow, D., Levron, J., Eldar-Geva, T., Hardan, I., Fridman, E. Zalel, Y. et al. (2005) Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med, 353, pp. 318-321.
38. Shaw, J. M., Bowels, J. and Koopman, P. (1996) Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod, 11, pp. 1668-1673.
39. Gosden, R. G., Rutherford, A. J. and Norfolk, D. R. (1997) Debate: ovarian banking for cancer patients-transmission of malignant cells in ovarian grafts. Hum Reprod, 12, p. 403.
40. Seshadri, T., Gook, D., Lade, S., Spencer, A., Grigg, A. Tiedemann, K. et al. (2006) Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer, 94, pp. 1007-1010.